Methyldopa Stada

Methyldopa, the active ingredient in Methyldopa Stada, is an alpha‑2 adrenergic agonist presented as an oral dosage form for oral use. It lowers blood pressure by reducing sympathetic outflow and is employed in the treatment of hypertension, including hypertension that occurs during pregnancy.

GNH USA supplies Methyldopa Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methyldopa acts on central alpha‑2 receptors to control elevated blood pressure in several clinical settings.

- Hypertension: lowers systemic arterial pressure in adults with essential or secondary hypertension. - Gestational hypertension: helps control blood pressure in pregnant women with hypertension. - Mild to moderate hypertension: provides an alternative when other antihypertensives are unsuitable or not tolerated.

Methyldopa may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Drowsiness or fatigue: central nervous system depression. - Headache: mild to moderate intensity. - Nasal congestion: sensation of blocked nose.

Serious or Rare Side Effects: - Severe anemia or hemolytic anemia: marked reduction in red blood cells. - Liver dysfunction: elevated transaminases or hepatitis. - Lupus‑like syndrome: arthralgia, rash, and serologic abnormalities. - Agranulocytosis: dangerously low white blood cell count. - Severe hypotension: abrupt and excessive drop in blood pressure.

When prescribing Methyldopa, clinicians should consider several safety measures.

- Blood pressure monitoring: adjust dose based on regular measurements. - Renal impairment: use caution and consider dose reduction. - Hepatic disease: monitor liver function tests periodically. - Discontinuation: avoid abrupt cessation to prevent rebound hypertension. - Hypersensitivity: do not use in patients with known allergy to methyldopa. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Methyldopa can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Clonidine: additive hypotensive effect leading to severe low blood pressure. - Tricyclic antidepressants: may blunt antihypertensive response.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive efficacy. - Alcohol: may increase sedation and dizziness.